Despite remarkable drug development efforts for some NR1 members, the therapeutic relevance of this protein family is still limited to a few targets and indications, such as PPARγ agonists in type 2 diabetes and RAR agonists in cancer. This evidence concerns the gene PPARG and type 2 diabetes mellitus.